提高一种既能降低死亡率又具有成本效益的新型药物治疗方法的采用和推广。
Increasing the Adoption and Diffusion of a Novel Pharmacological Therapy That Is Both Mortality Reducing and Cost-Effective.
机构信息
1 Department of Medicine Massachusetts General Hospital Harvard Medical School Boston MA.
2 Cardiology Division Department of Medicine Massachusetts General Hospital Harvard Medical School Boston MA.
出版信息
J Am Heart Assoc. 2019 Feb 5;8(3):e011783. doi: 10.1161/JAHA.118.011783.
Abstract
See Article by Luo et al
摘要
见罗等人的文章
相似文献
1
Increasing the Adoption and Diffusion of a Novel Pharmacological Therapy That Is Both Mortality Reducing and Cost-Effective.提高一种既能降低死亡率又具有成本效益的新型药物治疗方法的采用和推广。
J Am Heart Assoc. 2019 Feb 5;8(3):e011783. doi: 10.1161/JAHA.118.011783.
2
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.医院特征与心力衰竭住院患者中血管紧张素受体/脑啡肽酶抑制剂早期应用的关系。
J Am Heart Assoc. 2019 Feb 5;8(3):e010484. doi: 10.1161/JAHA.118.010484.
3
Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.沙库巴曲缬沙坦抑制中性肽链内切酶治疗心力衰竭：性价比高的降低死亡率方法
J Clin Pharm Ther. 2016 Apr;41(2):119-27. doi: 10.1111/jcpt.12363. Epub 2016 Mar 18.
4
Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.血管紧张素受体-中性肽链内切酶抑制剂治疗射血分数保留的心力衰竭可改善肾脏结局。
Circulation. 2020 Sep 29;142(13):1246-1248. doi: 10.1161/CIRCULATIONAHA.120.050398. Epub 2020 Sep 28.
5
Conflicting Perspectives on the Value of Neprilysin Inhibition in Heart Failure Revealed During Development of a Decision Aid Focusing on Patient Costs for Sacubitril/Valsartan.在开发一种关注沙库巴曲缬沙坦患者成本的决策辅助工具过程中，揭示了关于中性肽链内切酶抑制在心力衰竭中价值的相互矛盾的观点。
Circ Cardiovasc Qual Outcomes. 2020 Sep;13(9):e006255. doi: 10.1161/CIRCOUTCOMES.119.006255. Epub 2020 Aug 20.
6
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.心力衰竭的缬沙坦-沙库巴曲固定剂量复方制剂聚焦：迄今的证据
Drug Des Devel Ther. 2016 May 9;10:1627-39. doi: 10.2147/DDDT.S84782. eCollection 2016.
7
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.血管紧张素受体脑啡肽酶抑制剂沙库巴曲缬沙坦对荷兰射血分数降低的慢性心力衰竭患者的成本效益：基于荷兰既往和现行药物经济学指南的国家适应性分析
Value Health. 2017 Dec;20(10):1260-1269. doi: 10.1016/j.jval.2017.05.013. Epub 2017 Jun 20.
8
Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.将射血分数降低的心力衰竭患者转换为沙库巴曲缬沙坦治疗的成本效益：澳大利亚视角
Heart Lung Circ. 2020 Sep;29(9):1310-1317. doi: 10.1016/j.hlc.2019.03.007. Epub 2019 Apr 2.
9
Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions.射血分数范围内血管紧张素-中性肽链内切酶抑制剂的经济学评估
JAMA Cardiol. 2023 Nov 1;8(11):1048-1049. doi: 10.1001/jamacardio.2023.3223.
10
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.沙库巴曲缬沙坦钠联合治疗与依那普利治疗射血分数降低的心力衰竭的成本效果比较。
JACC Heart Fail. 2016 May;4(5):392-402. doi: 10.1016/j.jchf.2016.02.007. Epub 2016 Mar 30.
引用本文的文献
1
Disparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.晚期III期和IV期黑色素瘤患者在新型癌症治疗方法使用上的差异以及治疗结果的差异。
Immunotherapy. 2025 Jan;17(1):37-46. doi: 10.1080/1750743X.2025.2452836. Epub 2025 Jan 18.
2
Sociodemographic associations with uptake of novel therapies for acute myeloid leukemia.社会人口统计学因素与急性髓系白血病新型治疗方法的应用。
Blood Cancer J. 2023 Dec 21;13(1):192. doi: 10.1038/s41408-023-00964-x.
3
Translating Clinical Guidelines Into Care Delivery Innovation: The Importance of Rigorous Methods for Generating Evidence.将临床指南转化为护理服务创新：产生证据的严谨方法的重要性。
J Am Heart Assoc. 2022 Jul 5;11(13):e026677. doi: 10.1161/JAHA.122.026677. Epub 2022 Jun 29.
4
A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents?一个不应再犯的错误：从他汀类药物治疗的低使用率中，我们能学到什么以更有效地推广心脏保护的降糖药物？
Curr Cardiol Rep. 2022 Jun;24(6):689-698. doi: 10.1007/s11886-022-01694-5. Epub 2022 Mar 29.
5
Economic Issues in Heart Failure in the United States.美国心力衰竭的经济学问题。
J Card Fail. 2022 Mar;28(3):453-466. doi: 10.1016/j.cardfail.2021.12.017. Epub 2022 Jan 24.
6
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States.艾氯胺酮鼻喷雾剂在美国治疗抵抗性抑郁症患者中的成本效益
Psychiatr Serv. 2020 Oct 1;71(10):988-997. doi: 10.1176/appi.ps.201900625. Epub 2020 Jul 7.
本文引用的文献
1
Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.医院特征与心力衰竭住院患者中血管紧张素受体/脑啡肽酶抑制剂早期应用的关系。
J Am Heart Assoc. 2019 Feb 5;8(3):e010484. doi: 10.1161/JAHA.118.010484.
2
Cost-Effectiveness of Alirocumab: A Just-in-Time Analysis Based on the ODYSSEY Outcomes Trial.依洛尤单抗的成本效益：基于 ODYSSEY 结果试验的及时分析。
Ann Intern Med. 2019 Feb 19;170(4):221-229. doi: 10.7326/M18-1776. Epub 2019 Jan 1.
3
PCSK9 - A Journey to Cardiovascular Outcomes.前蛋白转化酶枯草溶菌素9——心血管结局之旅
N Engl J Med. 2018 Nov 29;379(22):2161-2162. doi: 10.1056/NEJMe1813758.
4
Overcoming Inertia to Improve Medication Use and Deprescribing.克服惰性以改善药物使用和减药
JAMA. 2018 Nov 13;320(18):1867-1869. doi: 10.1001/jama.2018.16473.
5
Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.解决 2 型糖尿病治疗惰性问题：综述
Adv Ther. 2018 Nov;35(11):1735-1745. doi: 10.1007/s12325-018-0819-5. Epub 2018 Oct 29.
6
Value-Based Pricing and Patient Access for Specialty Drugs.专科药物的价值定价与患者可及性
JAMA. 2018 Jun 5;319(21):2169-2170. doi: 10.1001/jama.2018.5367.
7
Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.临床动脉粥样硬化性心血管疾病或杂合子家族性高胆固醇血症合格患者中前蛋白转化酶枯草溶菌素9型抑制剂的处方模式
Am J Cardiol. 2018 May 15;121(10):1155-1161. doi: 10.1016/j.amjcard.2018.02.002. Epub 2018 Feb 12.
8
Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.预先授权和自付费用与患者获得 PCSK9 抑制剂治疗的关联。
JAMA Cardiol. 2017 Nov 1;2(11):1217-1225. doi: 10.1001/jamacardio.2017.3451.
9
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.基于FOURIER试验结果的PCSK9抑制剂最新成本效益分析
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.
10
Value-Based Pricing and State Reform of Prescription Drug Costs.基于价值的定价与处方药成本的国家改革。
JAMA. 2017 Aug 15;318(7):609-610. doi: 10.1001/jama.2017.8255.
Zotero 插件